About rilzabrutinib
Bruton's tyrosine kinase inhibitor
Used for
- Treats immune thrombocytopenia in adults who have not responded adequately to previous treatment.
Usual adult dose
400 mg by mouth twice daily; may be increased to 600 mg twice daily if needed.
Common side effects
- Diarrhea
- Nausea
- Headache
- Abdominal pain
Important warnings
- May increase infection risk; serious infections have occurred.
- Can cause bleeding; risk may be higher with other medicines affecting bleeding.
- Liver injury has occurred; liver tests may be monitored.
- Avoid live vaccines during treatment.
Pregnancy
There is limited information in humans; animal studies suggest possible fetal harm. Use during pregnancy is generally avoided.
Breastfeeding
It is not known whether rilzabrutinib passes into breast milk; breastfeeding is generally avoided during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase rilzabrutinib levels.
- Strong or moderate CYP3A inducers can reduce rilzabrutinib levels.
- May affect levels of some medicines transported by BCRP or P-glycoprotein.
- Other medicines that increase bleeding may raise bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.